Profile data is unavailable for this security.
About the company
3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.
- Revenue in -- (TTM)--
- Net income in --
- Incorporated2015
- Employees--
- Location3D Medicines IncSHANGHAI 201114ChinaCHN
- Phone+86 2 152210800
- Fax+86 1 067888635
- Websitehttps://www.3d-medicines.com/
More ▼
1.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 2.04m | 0.79% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 703.50k | 0.27% |
| E Fund Asset Management Co. Ltd.as of 31 Dec 2023 | 259.00k | 0.10% |
| China Asset Management (Hong Kong) Ltd.as of 31 May 2024 | 202.92k | 0.08% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 164.50k | 0.06% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 72.00k | 0.03% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 61.00k | 0.02% |
| Ping An Fund Management Co., Ltd.as of 31 Dec 2023 | 36.00k | 0.01% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 30.50k | 0.01% |
| Mercer Global Investments Europe Ltd.as of 30 Jun 2023 | 4.00k | 0.00% |
More ▼
Data from 31 Dec 2023 - 11 Jun 2024Source: FactSet Research Systems Inc.
